Meanwhile, the acquisition of AntlerA, which Roche called a leader in Wnt signaling, gives the pharma ownership of a library ...

Cambridge, Massachusetts-based biotech Regor Therapeutics Group has agreed to sell its portfolio of CDK inhibitors for the ...

The Swiss pharma is paying Regor Therapeutics $850 million to buy a pair of prospects it sees as potential successors to blockbuster medicines from Pfizer and Eli Lilly.

Genentech to buy Regor's portfolio of next-generation CDK inhibitors to treat breast cancer: Cambridge, Massachusetts Tuesday, October 1, 2024, 10:00 Hrs [IST] Regor Pharmaceutica ...

Sino-American biotech Regor Pharmaceuticals has entered into a definitive purchase agreement whereby Swiss pharma major Roche ...

Roche is spending $850 million upfront to buy Regor Pharmaceuticals’ suite of next-generation CDK inhibitors as it doubles ...

Regor Pharmaceuticals USA has entered into a definitive purchase agreement, under which Genentech, a member of the Roche Group, will ...

Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing ...

A major cyberattack on CDK Global, a software service used by thousands of car dealerships, is now impacting the public. The ...

A pair of cyberattacks against software maker CDK continues to impact thousands of car dealerships and has spurred threat actors to launch impersonation attacks. The CDK Global outage affecting ...

CDK Global reportedly paid $25 million to cybercriminals after a mid-June ransomware attack disrupted business for thousands of car dealerships. According to a report from CNN citing multiple ...

The night before June 19, Brian MacDonald attended a hockey game. The CDK Global CEO owns a home in Florida, and he capped his day driving two hours to see the Florida Panthers face off against ...